Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.

Trial Details

NCT ID
NCT06776172
Phase
NA
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Extended Pelvic Lymph Node Dissection
Locations (sample)
  • Aarau, Switzerland|47.39254,8.04422
  • Basel, Switzerland|47.55839,7.57327
  • Bern, Switzerland|46.94809,7.44744
  • Bern, Switzerland|46.94809,7.44744
  • Biel, Switzerland|46.45587,8.21773

Key Eligibility Criteria

  • Age ≥ 18 years and life expectancy \>15 years
  • Any biopsy-proven WHO/ISUP grade groups III-V PCa
  • High-risk prostate cancer defined as:
  • Any biopsy-proven WHO/ISUP grade group III-V PCa or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →